Document is current
Any future updates will be listed below
-
Authors
Gray, Melissa A.
Stanczak, Michal A.
Mantuano, Natália R.
Xiao, Han
Pijnenborg, Johan F. A.
Malaker, Stacy A. https://orcid.org/0000-0003-2382-5067
Miller, Caitlyn L. https://orcid.org/0000-0001-5120-7149
Weidenbacher, Payton A.
Tanzo, Julia T.
Ahn, Green
Woods, Elliot C.
Läubli, Heinz https://orcid.org/0000-0002-8910-5620
Bertozzi, Carolyn R. https://orcid.org/0000-0003-4482-2754
- License Information
-
More Information
Article History
Received: 23 May 2019
Accepted: 8 July 2020
First Online: 17 August 2020
Competing interests
: M.A.G., H.X., E.C.W. and C.R.B. are inventors of the patent filed by Stanford University (international publication number WO2018006034A1) titled ‘Conjugates for targeted cell-surface editing’ published on January 4, 2018 and licensed by Palleon Pharmaceuticals on 06/27/2017. C.R.B. is a cofounder and Scientific Advisory Board member of Palleon Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent) and InterVenn Biosciences, and a member of the Board of Directors of Eli Lilly & Company. H.L. received research and traveling support from Bristol-Myers Squibb. H.L. received traveling support from Merck Sharp Dome and Roche. H.L. is a member of the Scientific Advisory Board of Palleon Pharmaceuticals.
